RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Anavex Life Sciences - Stock

Anavex Life Sciences Stocks 2024

Anavex Life Sciences Stocks

79.79 M

Ticker

AVXL

ISIN

US0327973006

WKN

A1411S

In 2024, Anavex Life Sciences had 79.79 M outstanding stocks, a 0% change from the 79.79 M stocks in the previous year.

The Anavex Life Sciences Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2028e79.79
2027e79.79
2026e79.79
2025e79.79
2024e79.79
202379.79
202276.91
202169.8
202058.19
201948.91
201844.66
201740.84
201635.15
201518.58
20149.8
20137.98
20127.04
20116.29
20105.36
20095.05
20084.93
20074.8
20064.8

Anavex Life Sciences shares outstanding

The number of shares was Anavex Life Sciences in 2023 — This indicates how many shares 79.79 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Anavex Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Anavex Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Anavex Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Anavex Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Anavex Life Sciences Aktienanalyse

What does Anavex Life Sciences do?

Anavex Life Sciences Corp is a biotechnology company based in New York City that specializes in the development of novel drugs for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. The history of Anavex dates back to 2006 when a team of experts in neuroscience and pharmacology came together to explore the possibility of slowing down or even stopping the symptoms and progression of neurodegenerative diseases. Over the following years, Anavex developed several innovative therapeutic approaches based on the activation of the sigma-1 receptor. These receptors are part of the cellular signaling pathway and can reduce inflammation and oxidative damage in brain cells. Anavex's business model is focused on the development and marketing of novel drugs for neurodegenerative diseases. The company invests significant resources in researching the specific mechanisms of action of its various preparations. Anavex is focused on developing drugs for targeted treatment of neurodegenerative diseases, with a focus on Alzheimer's preparations. Anavex has several drugs in its pipeline at various stages of development, from preclinical research to clinical trials. The first drug developed by Anavex is the Anavex 2-73 preparation. This is a small molecule compound that has a high affinity for the sigma-1 receptor and can therefore reduce inflammation and oxidative damage in brain cells. Anavex 2-73 is in the clinical development phase, with promising results already obtained from phase 1 studies and open-label extension studies. The drug has the potential to slow down or even stop memory loss in patients with Alzheimer's disease. Anavex also has a promising drug in its pipeline that focuses on Parkinson's patients. The Anavex 3-71 preparation has been specifically developed to improve the cognitive functions of Parkinson's patients. It is a selective modulator of the sigma-1 receptor that has been designed to improve cognitive functions and enhance brain performance in connection with Parkinson's disease. In addition to Anavex 2-73 and Anavex 3-71, Anavex also has Anavex 1-41, which focuses on the treatment of Huntington's disease and other neurodegenerative diseases. Anavex 1-41 is a potentiator of the sigma-1 receptor, which, according to preclinical research results, has the potential to reduce oxidative damage in brain cells. Overall, the goal of Anavex is to develop novel drugs for the treatment of neurodegenerative diseases that target the specific mechanisms of these diseases and provide patients with a better quality of life. Overall, Anavex Life Sciences Corp is a biotechnology company that develops novel drugs for the treatment of neurodegenerative diseases. The company has focused on the activation of the sigma-1 receptor to slow down or even stop the progression and symptoms of Alzheimer's, Parkinson's, and Huntington's. Anavex has several products in different stages of development and has a team of experienced experts in neuroscience and pharmacology who focus on the development of innovative treatment concepts. Anavex Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Anavex Life Sciences's Shares Outstanding

Anavex Life Sciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Anavex Life Sciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Anavex Life Sciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Anavex Life Sciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Anavex Life Sciences Stock

How many stocks are there of Anavex Life Sciences?

The current number of stocks of Anavex Life Sciences is 79.79 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Anavex Life Sciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Anavex Life Sciences evolved in recent years?

The number of shares of Anavex Life Sciences has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Anavex Life Sciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Anavex Life Sciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Anavex Life Sciences pay?

Over the past 12 months, Anavex Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anavex Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Anavex Life Sciences?

The current dividend yield of Anavex Life Sciences is .

When does Anavex Life Sciences pay dividends?

Anavex Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anavex Life Sciences?

Anavex Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Anavex Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anavex Life Sciences located?

Anavex Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anavex Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anavex Life Sciences from 6/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Anavex Life Sciences pay the last dividend?

The last dividend was paid out on 6/28/2024.

What was the dividend of Anavex Life Sciences in the year 2023?

In the year 2023, Anavex Life Sciences distributed 0 USD as dividends.

In which currency does Anavex Life Sciences pay out the dividend?

The dividends of Anavex Life Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Anavex Life Sciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Anavex Life Sciences

Our stock analysis for Anavex Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Anavex Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.